Volume 29, Issue 1 (March 2025)
Physiol Pharmacol 2025, 29(1): 25-34 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bagheri M, Salari S. Unveiling the Cardiovascular Impact of Growth Hormone: Insights into Physiology, Pathology, and Therapy. Physiol Pharmacol 2025; 29 (1) : 3
URL: http://ppj.phypha.ir/article-1-2341-en.html
URL: http://ppj.phypha.ir/article-1-2341-en.html
Abstract: (502 Views)
The significance of height in boosting self-confidence has prompted some families to seek medical interventions to enhance their children’s stature. One such intervention is hormone therapy using recombinant human growth hormone (rhGH), which has been employed in clinics since 1985, primarily for treating growth hormone deficiency (GHD). Over time, rhGH therapy has been utilized for various conditions where childhood short stature is not solely a result of inadequate growth hormone secretion, such as small for gestational age (SGA) or idiopathic short stature (ISS). In addition to its effects on the skeletal system, growth hormone (GH) also plays a vital role in regulating cardiovascular function. There is growing evidence suggesting a correlation between abnormal GH levels—both elevated and deficient—and increased cardiovascular morbidity and mortality among patients with GH disorder. Notably, cardiovascular complications are not limited to pathological GH levels; even slight increases within the normal range have been linked to increased cardiovascular disease (CVD) events in healthy individuals. These findings raise concerns about the potential long-term cardiovascular effects of rhGH therapy, especially among children without GH disorders. In this comprehensive review, we summarized recent research findings to provide insights into the physiological and pathophysiological effects of GH on the heart. We aimed to elucidate the long-term side effects of GH therapy and identify associated risk factors.
Article number: 3
Keywords: Growth hormone, Insulin-Like Growth Factor I, cardiovascular diseases, Hormone Replacement Therapy
Type of Manuscript: Review |
Subject:
Endocrine Physiology/Pharmacology
References
1. Alkan F, Ersoy B, Kızılay D O, Coskun S. Cardiac functions in children with growth hormone deficiency: Effects of one year of GH replacement therapy. Growth Horm IGF Res 2021; 60-61: 101432. [DOI:10.1016/j.ghir.2021.101432]
2. Alkan F, Ersoy B, Kızılay D O, Ozyurt B C, Coskun S. Evaluation of cardiac structure, exercise capacity and electrocardiography parameters in children with partial and complete growth hormone deficiency and their changes with short term growth hormone replacement therapy. Pituitary 2023; 26: 115-123. [DOI:10.1007/s11102-022-01295-z]
3. Allard J B, Duan C. IGF-binding proteins: why do they exist and why are there so many? Frontiers in endocrinology 2018; 9: 117. [DOI:10.3389/fendo.2018.00117]
4. Birzniece V, Ho K K Y. Sex steroids and the GH axis: Implications for the management of hypopituitarism. Best Pract Res Clin Endocrinol Metab 2017; 31: 59-69. [DOI:10.1016/j.beem.2017.03.003]
5. Carel J C, Ecosse E, Landier F, Meguellati-Hakkas D, Kaguelidou F, Rey G, et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab 2012; 97: 416-425. [DOI:10.1210/jc.2011-1995]
6. Carter-Su C, Schwartz J, Argetsinger L S. Growth hormone signaling pathways. Growth Horm IGF Res 2016; 28: 11-5. [DOI:10.1016/j.ghir.2015.09.002]
7. Ceda G P, Davis R G, Rosenfeld R G, Hoffman A R. The growth hormone (GH)-releasing hormone (GHRH)-GH-somatomedin axis: evidence for rapid inhibition of GHRH-elicited GH release by insulin-like growth factors I and II. Endocrinology 1987; 120: 1658-1662. [DOI:10.1210/endo-120-4-1658]
8. Chen E Y, Liao Y-C, Smith D H, Barrera-Saldaña H A, Gelinas R E, Seeburg P H. The human growth hormone locus: nucleotide sequence, biology, and evolution. Genomics 1989; 4: 479-497. [DOI:10.1016/0888-7543(89)90271-1]
9. Ciresi A, Radellini S, Guarnotta V, Mineo M G, Giordano C. The metabolic outcomes of growth hormone treatment in children are gender specific. Endocr Connect 2018; 7: 879-887. [DOI:10.1530/EC-18-0135]
10. Cittadini A, Marra A M, Arcopinto M, Bobbio E, Salzano A, Sirico D, et al. Growth hormone replacement delays the progression of chronic heart failure combined with growth hormone deficiency: an extension of a randomized controlled single-blind study. JACC: Heart Failure 2013; 1: 325-330. [DOI:10.1016/j.jchf.2013.04.003]
11. Cittadini A, Monti M, Iaccarino G, Di Rella F, Tsichlis P, Di Gianni A, et al. Adenoviral gene transfer of Akt enhances myocardial contractility and intracellular calcium handling. Gene therapy 2006; 13: 8-19. [DOI:10.1038/sj.gt.3302589]
12. D’Amario D, Cabral-Da-Silva M C, Zheng H, Fiorini C, Goichberg P, Steadman E, et al. Insulin-like growth factor-1 receptor identifies a pool of human cardiac stem cells with superior therapeutic potential for myocardial regeneration. Circ Res 2011b; 108: 1467-1481. [DOI:10.1161/circresaha.111.240648]
13. Danielsson C, Brask J, Skold A C, Genead R, Andersson A, Andersson U, et al. Exploration of human, rat, and rabbit embryonic cardiomyocytes suggests K-channel block as a common teratogenic mechanism. Cardiovasc Res 2013; 97: 23-32. [DOI:10.1093/cvr/cvs296]
14. Danowitz M, Grimberg A. Clinical Indications for Growth Hormone Therapy. Adv Pediatr 2022; 69: 203-217. [DOI:10.1016/j.yapd.2022.03.005]
15. De Vos A M, Ultsch M, Kossiakoff A A. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 1992; 255: 306-312. [DOI:10.1126/science.1549776]
16. Dixit M, Poudel S B, Yakar S. Effects of GH/IGF axis on bone and cartilage. Mol Cell Endocrinol 2021; 519: 111052. [DOI:10.1016/j.mce.2020.111052]
17. Djordjijevic D, Zhang J, Priam M, Viollet C, Gourdji D, Kordon C, et al. Effect of 17beta-estradiol on somatostatin receptor expression and inhibitory effects on growth hormone and prolactin release in rat pituitary cell cultures. Endocrinology 1998; 139: 2272-2277. [DOI:10.1210/endo.139.5.5990]
18. Dutta P, Das S, Bhansali A, Bhadada S K, Rajesh B V, Reddy K S, et al. Congestive heart failure in acromegaly: A review of 6 cases. Indian J Endocrinol Metab 2012; 16: 987-990. [DOI:10.4103/2230-8210.103007]
19. Elaiopoulos D A, Tsalikakis D G, Agelaki M G, Baltogiannis G G, Mitsi A C, Fotiadis D I, et al. Growth hormone decreases phase II ventricular tachyarrhythmias during acute myocardial infarction in rats. Clin Sci (Lond) 2007; 112: 385-391. [DOI:10.1042/CS20060193]
20. Fahanik-Babaei J, Bagheri M, Salari S. Characterization of a novel Ca(2+)-Activated potassium channel in rat brain rough endoplasmic reticulum. Arch Biochem Biophys 2024; 759: 110105. [DOI:10.1016/j.abb.2024.110105]
21. Fahanik-Babaei J, Eliassi A, Jafari A, Sauve R, Salari S, Saghiri R. Electro-pharmacological profile of a mitochondrial inner membrane big-potassium channel from rat brain. Biochim Biophys Acta 2011; 1808: 454-460. [DOI:10.1016/j.bbamem.2010.10.005]
22. Fodor M, Csaba Z, Kordon C, Epelbaum J. Growth hormone-releasing hormone, somatostatin, galanin and beta-endorphin afferents to the hypothalamic periventricular nucleus. J Chem Neuroanat 1994; 8: 61-73. [DOI:10.1016/0891-0618(94)90036-1]
23. Galoiu S, Toma I D, Tanasie D I, Barbulescu A, Baciu I, Niculescu D A, et al. High mortality risk among women with acromegaly still persists. Front Endocrinol (Lausanne) 2024; 15: 1348972. [DOI:10.3389/fendo.2024.1348972]
24. Găloiu S, Toma I D, Tănasie D I, Bărbulescu A, Baciu I, Niculescu D A, et al. High mortality risk among women with acromegaly still persists. Front Endocrinol (Lausanne) 2024; 15: 1348972. [DOI:10.3389/fendo.2024.1348972]
25. Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 2008; 29: 535-559. [DOI:10.1210/er.2007-0036]
26. Goedegebuure W J, van der Steen M, Smeets C C J, Hokken-Koelega A C S. Childhood growth hormone treatment and metabolic and cardiovascular risk in adults born small for gestational age after growth hormone cessation in the Netherlands: a 12-year follow-up study. Lancet Child Adolesc Health 2022; 6: 777-787. [DOI:10.1016/S2352-4642(22)00240-1]
27. Hallengren E, Almgren P, Engström G, Hedblad B, Persson M, Suhr J, et al. Fasting levels of high-sensitivity growth hormone predict cardiovascular morbidity and mortality: the Malmö Diet and Cancer study. J Am Coll Cardiol 2014; 64: 1452-1460. [DOI:10.1016/j.jacc.2014.03.063]
28. Hartman M L, Veldhuis J D, Thorner M O. Normal control of growth hormone secretion. Horm Res 1993; 40: 37-47. [DOI:10.1159/000183766]
29. Higaki K, Matsumoto Y, Fujimoto R, Kurosaki Y, Kimura T. Pharmacokinetics of recombinant human insulin-like growth factor-I in diabetic rats. Drug Metab Dispos 1997; 25: 1324-1327.
30. Isgaard J, Arcopinto M, Karason K, Cittadini A. GH and the cardiovascular system: an update on a topic at heart. Endocrine 2015; 48: 25-35. [DOI:10.1007/s12020-014-0327-6]
31. Ito H, Hiroe M, Hirata Y, Tsujino M, Adachi S, Shichiri M, et al. Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation 1993; 87: 1715-1721. [DOI:10.1161/01.CIR.87.5.1715]
32. Jehle P M, Schulten K, Schulz W, Jehle D R, Stracke S, Manfras B, et al. Serum levels of insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-1 to -6 and their relationship to bone metabolism in osteoporosis patients. Eur J Intern Med 2003; 14: 32-38. [DOI:10.1016/S0953-6205(02)00183-8]
33. Jin H, Yang R, Lu H, Ogasawara A K, Li W, Ryan A, et al. Effects of early treatment with growth hormone on infarct size, survival, and cardiac gene expression after acute myocardial infarction. Growth Horm IGF Res 2002; 12: 208-215. [DOI:10.1016/S1096-6374(02)00042-4]
34. Johansson A G, Engström B E, Ljunghall S, Karlsson F A, Burman P. Gender differences in the effects of long term growth hormone (GH) treatment on bone in adults with GH deficiency. J Clin Endocrinol Metab 1999; 84: 2002-2007. [DOI:10.1210/jcem.84.6.5743]
35. Kahaly G, Olshausen K V, Mohr-Kahaly S, Erbel R, Boor S, Beyer J, et al. Arrhythmia profile in acromegaly. Eur Heart J 1992; 13: 51-56. [DOI:10.1093/oxfordjournals.eurheartj.a060047]
36. Kenchegowda D, Legesse B, Hritzo B, Olsen C, Aghdam S, Kaur A, et al. Selective insulin-like growth factor resistance associated with heart hemorrhages and poor prognosis in a novel preclinical model of the hematopoietic acute radiation syndrome. Radiat Res 2018; 190: 164-175. [DOI:10.1667/RR14993.1]
37. Kolettis T M. Coronary artery disease and ventricular tachyarrhythmia: pathophysiology and treatment. Curr Opin Pharmacol 2013; 13: 210-217. [DOI:10.1016/j.coph.2013.01.001]
38. Kontonika M, Barka E, Roumpi M, La Rocca V, Lekkas P, Daskalopoulos E P, et al. Prolonged intra-myocardial growth hormone administration ameliorates post-infarction electrophysiologic remodeling in rats. Growth Factors 2017; 35: 1-11. [DOI:10.1080/08977194.2017.1297432]
39. Liliya R, Adrian D, Nalini S, Luciana A N, Anne B, Marie-Lise J-R, et al. Cardiovascular complications in pituitary gigantism (results of an international study). Journal 2018; 57. [DOI:10.1530/endoabs.57.021]
40. Lombardi G, Colao A, Marzullo P, Biondi B, Palmieri E, Fazio S. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. J Endocrinol Invest 2002; 25: 971-976. [DOI:10.1007/BF03344070]
41. Lombardi G, Di Somma C, Grasso L, Savanelli M, Colao A, Pivonello R. The cardiovascular system in growth hormone excess and growth hormone deficiency. Journal of endocrinological investigation 2012; 35: 1021-1029.
42. Lu C, Schwartzbauer G, Sperling M A, Devaskar S U, Thamotharan S, Robbins P D, et al. Demonstration of direct effects of growth hormone on neonatal cardiomyocytes. J Biol Chem 2001; 276: 22892-22900. [DOI:10.1074/jbc.M011647200]
43. Ma Y, Zhang L, Launikonis B S, Chen C. Growth hormone secretagogues preserve the electrophysiological properties of mouse cardiomyocytes isolated from in vitro ischemia/reperfusion heart. Endocrinology 2012; 153: 5480-5490. [DOI:10.1210/en.2012-1404]
44. Mizera L, Elbaum M, Daroszewski J, Bolanowski M. Cardiovascular complications of acromegaly. Acta Endocrinol (Buchar) 2018a; 14: 365-374. [DOI:10.4183/aeb.2018.365]
45. Obradovic M, Zafirovic S, Soskic S, Stanimirovic J, Trpkovic A, Jevremovic D, et al. Effects of IGF-1 on the cardiovascular system. Current Pharmaceutical Design 2019; 25: 3715-3725. [DOI:10.2174/1381612825666191106091507]
46. Orosz A, Csajbók É, Czékus C, Gavallér H, Magony S, Valkusz Z, et al. Increased short-term beat-to-beat variability of QT interval in patients with acromegaly. PLoS One 2015; 10: e0125639. [DOI:10.1371/journal.pone.0125639]
47. Ramos-Leví A M, Marazuela M. Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management. Endocrine 2017; 55: 346-359. [DOI:10.1007/s12020-016-1191-3]
48. Råmunddal T, Gizurarson S, Lorentzon M, Omerovic E. Antiarrhythmic effects of growth hormone--in vivo evidence from small-animal models of acute myocardial infarction and invasive electrophysiology. J Electrocardiol 2008; 41: 144-151. [DOI:10.1016/j.jelectrocard.2007.09.002]
49. Ravingerova T, Slezak J, Tribulova N, Dzurba A, Uhrik B, Ziegelhoffer A. High arrythmogenesis during early reperfusion of ischaemic myocardium: participation of oxygen free radicals. J Basic Clin Physiol Pharmacol 1993; 4: 335-346. [DOI:10.1515/JBCPP.1993.4.4.335]
50. Richmond E, Rogol A D. Current indications for growth hormone therapy for children and adolescents. Endocr Dev 2010; 18: 92-108. [DOI:10.1159/000316130]
51. Ritvonen E, Loyttyniemi E, Jaatinen P, Ebeling T, Moilanen L, Nuutila P, et al. Mortality in acromegaly: a 20-year follow-up study. Endocr Relat Cancer 2016; 23: 469-480. [DOI:10.1530/ERC-16-0106]
52. Salari S, Eliassi A A, Saghiri R. Evidences on the existence of a new potassium channel in the rough endoplasmic reticulum (RER) of rat hepatocytes. Physiology and Pharmacology 2011; 15: 16-26.
53. Salari S, Ghasemi M, Fahanik-Babaei J, Saghiri R, Sauve R, Eliassi A. Evidence for a KATP channel in rough endoplasmic reticulum (rerKATP Channel) of rat hepatocytes. PLoS One 2015; 10: e0125798. [DOI:10.1371/journal.pone.0125798]
54. Salari S, Silverå Ejneby M, Brask J, Elinder F. Isopimaric acid - a multi-targeting ion channel modulator reducing excitability and arrhythmicity in a spontaneously beating mouse atrial cell line. Acta Physiol (Oxf) 2018; 222. [DOI:10.1111/apha.12895]
55. Sánchez-Aguilera P, López-Crisosto C, Norambuena-Soto I, Penannen C, Zhu J, Bomer N, et al. IGF-1 boosts mitochondrial function by a Ca(2+) uptake-dependent mechanism in cultured human and rat cardiomyocytes. Front Physiol 2023; 14: 1106662. [DOI:10.3389/fphys.2023.1106662]
56. Sävendahl L, Blankenstein O, Oliver I, Christesen H T, Lee P, Pedersen B T, et al. Gender influences short-term growth hormone treatment response in children. Horm Res Paediatr 2012a; 77: 188-194. [DOI:10.1159/000337570]
57. Sävendahl L, Cooke R, Tidblad A, Beckers D, Butler G, Cianfarani S, et al. Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study. The lancet Diabetes & endocrinology 2020; 8: 683-692. [DOI:10.1016/S2213-8587(20)30163-7]
58. Sävendahl L, Maes M, Albertsson-Wikland K, Borgström B, Carel J C, Henrard S, et al. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab 2012b; 97: E213-E217. [DOI:10.1210/jc.2011-2882]
59. Solem M L, Thomas A P. Modulation of cardiac Ca2+ channels by IGF1. Biochemical and Biophysical Research Communications 1998; 252: 151-155. [DOI:10.1006/bbrc.1998.9626]
60. Span J P, Pieters G F, Sweep C G, Hermus A R, Smals A G. Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement. J Clin Endocrinol Metab 2000; 85: 1121-1125. [DOI:10.1210/jcem.85.3.6463]
61. Stamatis K V, Kontonika M, Daskalopoulos E P, Kolettis T M. Electrophysiologic effects of growth hormone post-myocardial infarction. Int J Mol Sci 2020; 21. [DOI:10.3390/ijms21030918]
62. Subramnaian M, Shah V, Saggu D K, Yalagudri S, Narasimhan C. Looking above the heart: A rare cause of ventricular tachycardia. J Arrhythm 2021; 37: 1120-1122. [DOI:10.1002/joa3.12546]
63. Teos L Y, Zhao A, Alvin Z, Laurence G G, Li C, Haddad G E. Basal and IGF-I-dependent regulation of potassium channels by MAP kinases and PI3-kinase during eccentric cardiac hypertrophy. Am J Physiol Heart Circ Physiol 2008; 295: 1834-1845. [DOI:10.1152/ajpheart.321.2008]
64. Tidblad A, Bottai M, Kieler H, Albertsson-Wikland K, Sävendahl L. Association of childhood growth hormone treatment with long-term cardiovascular morbidity. JAMA pediatrics 2021; 175: e205199-e205199. [DOI:10.1001/jamapediatrics.2020.5199]
65. Troncoso R, Ibarra C, Vicencio J M, Jaimovich E, Lavandero S. New insights into IGF-1 signaling in the heart. Trends in Endocrinology & Metabolism 2014; 25: 128-137. [DOI:10.1016/j.tem.2013.12.002]
66. van Bunderen C C, Olsson D S. Growth hormone deficiency and replacement therapy in adults: Impact on survival. Rev Endocr Metab Disord 2021; 22: 125-133. [DOI:10.1007/s11154-020-09599-w]
67. van Bunderen C C, van Nieuwpoort I C, Arwert L I, Heymans M W, Franken A A, Koppeschaar H P, et al. Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in adults. J Clin Endocrinol Metab 2011; 96: 3151-3159. [DOI:10.1210/jc.2011-1215]
68. Vance M L, Mauras N. Growth hormone therapy in adults and children. New England Journal of Medicine 1999; 341: 1206-1216. [DOI:10.1056/NEJM199910143411607]
69. Werner H. The IGF1 Signaling pathway: From basic concepts to therapeutic opportunities. Int J Mol Sci 2023; 24. [DOI:10.3390/ijms241914882]
70. Wolters T L C, Netea M G, Riksen N P, Hermus A, Netea-Maier R T. Acromegaly, inflammation and cardiovascular disease: a review. Rev Endocr Metab Disord 2020; 21: 547-568. [DOI:10.1007/s11154-020-09560-x]
71. Xu X P, Best P M. Decreased transient outward K+ current in ventricular myocytes from acromegalic rats. Am J Physiol 1991; 260: H935-942. [DOI:10.1152/ajpheart.1991.260.3.H935]
72. Xu X P, Best P M. Increase in T-type calcium current in atrial myocytes from adult rats with growth hormone-secreting tumors. Proc Natl Acad Sci U S A 1990; 87: 4655-4659. [DOI:10.1073/pnas.87.12.4655]
73. Yang R, Bunting S, Gillett N, Clark R, Jin H. Growth hormone improves cardiac performance in experimental heart failure. Circulation 1995; 92: 262-267. [DOI:10.1161/01.CIR.92.2.262]
74. Yilmaz M, Gurses D, Ata A. Electrocardiographic findings in children with growth hormone deficiency. Cureus 2023; 15: e36385. [DOI:10.7759/cureus.36385]
75. Yu Y M, Domené H M, Sztein J, Counts D R, Cassorla F. Developmental changes and differential regulation by testosterone and estradiol of growth hormone receptor expression in the rabbit. Eur J Endocrinol 1996; 135: 583-590. [DOI:10.1530/eje.0.1350583]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
